Previous 10 | Next 10 |
Minerva Neurosciences (NASDAQ:NERV): Q3 GAAP EPS of -$0.22 misses by $0.01 Cash, cash equivalents, restricted cash and marketable securities as of September 30, 2021 were approximately $65.7M. Shares +9.67% PM Press Release For further details see: Minerva Neurosciences EPS mi...
Company to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, tod...
Minerva Neurosciences (NASDAQ:NERV) is scheduled to announce Q3 earnings results on Monday, November 8th, before market open. The consensus EPS Estimate is -$0.22 (-15.8% Y/Y) and the consensus Revenue Estimate is $0.2M Over the last 3 months, EPS estimates have seen 1 upward revision and 2 d...
AVDL, AXSM, BKI, COTY, CTRE, DS,EDIT, EHTH, IMOS, KOS, LINC, LTBR, MTNB, NERV, OCN, PSEC, RDUS, RETA, TGLS, THS, TSEM, TTD, TYME, USFD, VAC, VTRS, WOW For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
Minerva Neurosciences (NASDAQ:NERV) shares fall 4% premarket after the U.S. FDA denied the company’s request for a pre-NDA meeting for roluperidone. The health regulator responded that a Type C guidance meeting would be more appropriate to discuss the evidence for use of rolu...
WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the U. S. Food and Drug Administration (FDA)...
WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and b...
Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of ...
Futures are up over 0.4% in the pre-market sessions and it looks like it will be a bull’s day today. Futures on the Dow Jones Industrial Average gained 151 points, or 0.47%. S&P 500 futures rose 0.44% while Nasdaq 100 futures added 0.4%. Treasury Secretary Janet Yellen cautioned Tu...
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced results from a pivotal bioequivalence study comparing ...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...